Optimizing Clinical and Economic Outcomes in the Management of Primary Immunodeficiency Diseases (PIDD): What Managed Care Needs to Know
About Immunoglobulin Replacement Therapy
 

A continuing medical education activity sponsored by NAMCP and AAMCN

This webinar series will provide critical updates on the advances in immunotherapies, including how
to translate the most recent data into clinical and administrative practice.

These are archives of live webinars held between December 4 to December 13, 2019.
If you participated in any of the live webinars, you are not eligible to claim credit from the archive of that webinar.

By clicking on each of the titles, you will be able to participate in each part.
It is not required that you participate in all 3 or in order.

Each session has its own specific valid dates

This series is supported by an educational grant from CSL Behring
 

 Audience: This activity is intended for healthcare professionals practicing in managed care environments.

 

Instructions for CME/CNE: Complete the pre-test, listen to the audio and view the slides, complete the post test, complete the evaluation form and hit submit. You will be asked to enter your name and email address on the pre-test, evaluation and post-test. If you close your internet browser without completing the post test, you will have ONE more opportunity to complete. A score of 70% must be achieved on the post test to receive continuing education credits. If you do not pass the post test after two attempts, you will not be eligible to try again. Once you complete the evaluation form and score 70% or higher on your post test, you will automatically be given your certificate.

Description:
Primary immunodeficiency diseases (PIDD) are a group of more than 300 rare, chronic disorders in which part of the body's immune system is missing or functions improperly. While not contagious, these diseases are caused by hereditary or genetic defects, and, although some disorders present at birth or in early childhood, the disorders can affect anyone, regardless of age or gender. Fortunately for patients with PIDD, the treatment paradigm has exploded in the past 10 years, giving HCPs many more options in managing the patient population. This live webinar series will feature strategies to overcome challenges in the optimal treatment of PIDD, updates on immunoglobulin replacement therapies, and practical managed care approaches to provide cost-effective solutions to improve both clinical and economic outcomes. 


A Deeper Look into Immunoglobulin Replacement in the Management of Primary Immunodeficiency Diseases (PIDD): Individualizing Treatment for Improved Clinical and Economic Outcomes

  1. Identify patients who may have a primary immunodeficiency disease (PIDD) and discuss appropriate tests to diagnose the disease
  2. Examine the history of immunoglobulin (Ig) therapy in PIDD and its rationale for use
  3. Compare and contrast the different immunoglobulin products and their FDA-approved indications, sodium and sugar contents, and adverse effects
  4. Differentiate the key differences between subcutaneous and intravenous therapy, including the advantages and disadvantages of both options in various patient populations
       Physician, Nursing and CMCN credits valid to January 1, 2022

Improving Patient Adherence and Quality of Life in PIDD: Strategies for Improving Administration and Managing Adverse Events

  1. Explore challenges to patient adherence and quality of life in PIDD and discuss strategies to overcome those challenges
  2. Analyze recent updates on dosing and administration of Ig replacement therapy in the management of PIDD
  3. Discuss individualized PIDD treatment strategies, taking into consideration risks and benefits of therapies, adverse events, disease characteristics and severity, comorbid conditions, patient quality of life, and patient preference
  4. Examine adverse events commonly associated with Ig replacement therapies used in PIDD management
  5. Differentiate the key differences between subcutaneous and intravenous therapy, including the advantages and disadvantages of both options in various patient populations
       Physician, Nursing and CMCN credits valid to January 1, 2022

Comparative Effectiveness and Coordinated Care in PIDD: What Does Managed Care Need to Know about Immunoglobulin Replacement Therapy?

  1. Explore the total cost of care for PIDD, including direct costs associated with drug therapy and associated infections from non-treatment, as well as indirect costs
  2. Assess recent pharmacoeconomic studies pertaining to Ig replacement therapy and the budgetary implications of these data in a managed care framework
  3. Apply methods to enable optimal cost management of Ig replacement therapy to be realized by multiple PIDD stakeholders including managed care organizations
  4. Analyze strategies used by managed care organizations to facilitate high quality care for members with PIDD, and how Ig replacement therapies affect those strategies
      Physician, Nursing and CMCN credits valid to January 1, 2022